Effects of acupuncture and Chinese herbal medicine (Zhi Mu 14) on hot flushes and quality of life in postmenopausal women: results of a four-arm randomized controlled pilot trial

OBJECTIVE: The aim of this study was to evaluate the feasibility of a clinical trial investigating the effects of acupuncture (AP) and Chinese herbal medicine (CHM) on hot flushes and quality of life in postmenopausal women. METHODS: Forty postmenopausal women reporting at least 20 hot flushes per week were enrolled in a randomized controlled trial. They were randomly allocated to receive traditional Chinese medicine (TCM) AP, sham AP, verum CHM, or placebo CHM for 12 weeks. Follow-up assessment was conducted 12 weeks after intervention. Primary outcome measures included hot flush frequency and severity. As a secondary outcome measure, the severity of menopausal symptoms was assessed using the Menopause Rating Scale (MRS) II. RESULTS: TCM AP induced a significant decline in all outcome measures from pretreatment to posttreatment compared with sham AP (hot flush frequency, P = 0.016; hot flush severity, P = 0.013; MRS, P < 0.001). In the TCM AP group, a larger decrease in MRS scores persisted from pretreatment to follow-up (P = 0.048). No significant differences were noted between the verum CHM group and the placebo CHM group. Compared with the verum CHM group, there was a significant decrease in MRS scores (P = 0.002) and a trend toward a stronger decrease in hot flush severity (P = 0.06) in the TCM AP group from pretreatment to posttreatment. CONCLUSIONS: TCM AP is superior to sham AP and verum CHM in reducing menopausal symptoms, whereas verum CHM shows no significant improvements when compared with placebo CHM.

Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes

AIMS: We investigated whether myeloid-related protein 8/14 complex (MRP8/14) expressed by infiltrating monocytes and granulocytes may represent a mediator and early biomarker of acute coronary syndromes (ACS). METHODS AND RESULTS: Immunohistochemistry of coronary thrombi was done in 41 ACS patients. Subsequently, levels of MRP8/14 were assessed systemically in 75 patients with ACS and culprit lesions, with stable coronary artery disease (CAD), or with normal coronary arteries. In a subset of patients, MRP8/14 was measured systemically and at the site of coronary occlusion. Macrophages and granulocytes, but not platelets stained positive for MRP8/14 in 76% of 41 thrombi patients. In ACS, local MRP8/14 levels [22.0 (16.2-41.5) mg/L] were increased when compared with systemic levels [13.4 (8.1-14.7) mg/L, P = 0.03]. Systemic levels of MRP8/14 were markedly elevated [15.1 (12.1-21.8) mg/L, P = 0.001] in ACS when compared with stable CAD [4.6 (3.5-7.1) mg/L] or normals [4.8 (4.0-6.3) mg/L]. Using a cut-off level of 8 mg/L, MRP8/14 but not myoglobin or troponin, identified ACS presenting within 3 h from symptom onset. CONCLUSION: In ACS, MRP8/14 is markedly expressed at the site of coronary occlusion by invading phagocytes. The occurrence of elevated MRP8/14 in the systemic circulation prior to markers of myocardial necrosis makes it a prime candidate for the detection of unstable plaques and management of ACS.

Evaluation of 15 mandibular reconstructions with Dumbach Titan Mesh-System and particulate cancellous bone and marrow harvested from bilateral posterior ilia

This study reports on 15 mandibular reconstructions using the Dumbach Titan Mesh-System and particulate cancellous bone and marrow harvested from bilateral posterior ilia. All cases showed segmental defects. Eleven cases involved patients with malignant tumor. Six patients had received irradiation of 40-50 Gy. Reconstructions were performed immediately in 1 patient and secondarily in the remaining 14 patients. In 13 cases, mandibles were successfully reconstructed. Of these 13 patients, 9 reconstructions were completed without complications, whereas the other 4 cases showed complications. In 2 cases, reconstruction failed completely. Overall success rate was 87%. Statistical analysis revealed the extent of mandibular defect, but not malignancy of the original disease or radiotherapy of

Neonatal procedural pain exposure and pain management in ventilated preterm infants during the first 14 days of life

OBJECTIVES: Ventilated preterm infants are at high risk for procedural pain exposure. In Switzerland there is a lack of knowledge about the pain management in this highly vulnerable patient population. The aims of this study were to describe the type and frequency of procedures and to determine the amount of analgesia given to this patient group in two Swiss neonatal intensive care units. METHOD: A retrospective cohort study was performed examining procedural exposure and pain management of a convenience sample of 120 ventilated preterm infants (mean age = 29.7 weeks of gestation) during the first 14 days of life after delivery and born between May 1st 2004 and March 31st 2006. RESULTS: The total number of procedures all the infants underwent was 38,626 indicating a mean of 22.9 general procedures performed per child and day. Overall, 75.6% of these procedures are considered to be painful. The most frequently performed procedure is manipulation on the CPAP prongs. Pain measurements were performed four to seven times per day. In all, 99.2% of the infants received either non-pharmacological and/or pharmacological agents and 70.8% received orally administered glucose as pre-emptive analgesia. Morphine was the most commonly used pharmacological agent. DISCUSSION: The number of procedures ventilated preterm infants are exposed to is disconcerting. Iatrogenic pain is a serious problem, particularly in preterm infants of low gestational age. The fact that nurses assessed pain on average four to seven times daily per infant indicates a commitment to exploring a painful state in a highly vulnerable patient population. In general, pharmacological pain management and the administration of oral glucose as a non-pharmacological pain relieving intervention appear to be adequate, but there may be deficiencies, particularly for extremely low birth weight infants born <28 weeks of gestation.

Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15

We report on the re-examination of nine Australian isolates of Actinobacillus pleuropneumoniae that have been previously assigned to serovar 12. In the ring precipitation test, none of the nine isolates reacted with antisera to serovars 1-14 of A. pleuropneumoniae. Antiserum prepared against one of the Australian isolates gave no reaction with any of the 14 recognised serovar reference strains, except serovar 7. This reaction of the HS143 antiserum with serovar 7 antigen could be removed by adsorption with serovar 7 antigen. The adsorbed antiserum remained reactive with HS143 and the other eight Australian isolates. The nine Australian isolates were all shown to express ApxII and ApxIII, found in serovars 2, 4, 6 and 8, as well as the 42kDa outer membrane protein found in all serovars of A. pleuropneumoniae. The nine Australian isolates were found to possess the following toxin associated genes apxIBD, apxIICA, apxIIICA, apxIIIBD and apxIVA. The toxin gene profile of the Australian isolates is typical of A. pleuropneumoniae serovars 2, 4, 6 and 8. On the basis of the serological characterisation results and the toxin gene profiles, we propose that these isolates represent a new serovar of A. pleuropneumoniae--serovar 15--with HS143 being the reference strain for the new serovar.

Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)

INTRODUCTION Small-cell lung cancer (SCLC) is a highly vascularized tumor. ASA404 is a tumor vascular disrupting agent. This is the first trial to report the effects of combining chemotherapy with ASA404 in SCLC. METHODS Patients with untreated metastatic SCLC were treated with carboplatin (area under curve, 6) plus paclitaxel (175 mg/m(2)) plus ASA404 (1800 mg/m(2)) on day 1 every 21 days for up to 6 cycles. The primary endpoint was the progression-free survival (PFS) rate at 24 weeks. RESULTS Median age was 61 years; 53% were women, 41% had weight loss; and 96% had a performance status of 0-1. Twelve patients completed all 6 cycles, and most adverse events were related to chemotherapy. Median PFS and time to progression were 7.0 months (95% CI, 5.7-9.4 months) and 7.5 months (95% CI, 5.7-9.4 months), respectively. The progression-free survival (PFS) rate at 24 weeks was 41% (95% CI, 18%-65%). The overall response rate was 94%. The median overall survival time was 14.2 months (95% CI, 8.2-16.0 months) and 1-year survival was 57%. The median follow-up time was 17.7 months. Due to negative results with ASA404 in non-small-cell lung cancer trials, the trial was stopped prematurely after 17 of 56 planned patients were being accrued. CONCLUSIONS This is the first report of a clinical trial with a vascular disrupting agent in SCLC. No unexpected toxicity was observed. PFS was not prolonged with carboplatin and paclitaxel plus ASA404.

Improving a gas ion source for C-14 AMS

For more than 4 years, gaseous samples of 1-50 mu g carbon have been routinely measured with the gas ion source of the small AMS (Accelerator Mass Spectrometer) facility MICADAS (Mini CArbon DAting System) at ETH Zurich. The applied measurement technique offers a simple and fast way of C-14 measurements without the need of sample graphitization. A major drawback of gaseous C-14 measurements, however, is the relatively low negative ion current, which results in longer measurement times and lower precision compared to graphitized samples. In December 2009, a new, improved Cs sputter ion source was installed at MICADAS and we began to optimize conditions for the measurement of gaseous samples. C-12(-) currents from the new ion source were improved from initially 3 to 12-15 mu A for routine measurements and the negative ion yield was increased by a factor of 2, reaching 8 on average during routine operation. Moreover, the new measurement settings enable a doubled CO2 flow, thus substantially reducing measurement times. The achieved performance allows closing the sample size gap between gaseous and solid samples and makes the gas ion source a promising tool for dating with a measurement precision of 5 parts per thousand on samples as small as 50 mu g carbon. (C) 2012 Elsevier B.V. All rights reserved.

Costs and yield of a 15-month preparticipation cardiovascular examination with ECG in 1070 young athletes in Switzerland: implications for routine ECG screening

Background The usefulness and modalities of cardiovascular screening in young athletes remain controversial, particularly concerning the role of 12-lead ECG. One of the reasons refers to the presumed false-positive ECGs requiring additional examinations and higher costs. Our study aimed to assess the total costs and yield of a preparticipation cardiovascular examination with ECG in young athletes in Switzerland. Methods Athletes aged 14–35 years were examined according to the 2005 European Society of Cardiology (ESC) protocol. ECGs were interpreted based on the 2010 ESC-adapted recommendations. The costs of the overall screening programme until diagnosis were calculated according to Swiss medical rates. Results A total of 1070 athletes were examined (75% men, 19.7±6.3 years) over a 15-month period. Among them, 67 (6.3%) required further examinations: 14 (1.3%) due to medical history, 15 (1.4%) due to physical examination and 42 (3.9%) because of abnormal ECG findings. A previously unknown cardiac abnormality was established in 11 athletes (1.0%). In four athletes (0.4%), the abnormality may potentially lead to sudden cardiac death and all of them were identified by ECG alone. The cost was 157 464 Swiss francs (CHF) for the overall programme, CHF147 per athlete and CHF14 315  per finding. Conclusions Cardiovascular preparticipation examination in young athletes using modern and athlete-specific criteria for interpreting ECG is feasible in Switzerland at reasonable cost. ECG alone is used to detect all potentially lethal cardiac diseases. The results of our study support the inclusion of ECG in routine preparticipation screening.

1849: Präsenz-Liste*) der Mannschaft des Rheinhessischen Freischärler-Bataillons vom 16. Mai bis 14. Juni 1849: Hauptquartier Kirchheimbolanden

Welsch (Projektbearbeiter): Reichsverfassungskampagne in der linksrheinischen Pfalz: Nach der Bildung einer 'Provisorischen Regierung der Pfalz' durch die direkt gewählten Vertreter der 28 pfälzischen Kantone am 17. Mai 1849 in Kaiserslautern erfolgt am 13. Juni 1849 von Norden her der Einmarsch preußischer Truppen. Am 14. Juni 1849 fallen im Schloßgarten von Kirchheimbolanden 17 Freischärler im Kampf gegen die Preußen

Offizieller Bericht über den Kampf vom 15. Juni 1849: Sieg der Unsern an allen Orten unter dem Oberbefehl des Generals Mieroslawski! Der Kampf begann des Morgens um 10 Uhr gleichzeitig an vier Punkten ...

Welsch (Projektbearbeiter): Bericht über den erfolgreichen Widerstand der badisch-pfälzischen Revolutionsarmee, der im Kampf gegen die aus Richtung Westen und Norden anrückenden Bundestruppen die Einnahme von Käfertal und Ladenburg gelingt. "... angesichts der numerischen Überlegenheit des Feindes [war jedoch] die Neckarlinie auf Dauer nicht zu halten ..." [1848/49: Rev. d. dt. Demokraten in Baden; Baden-Baden 1998, S. 372]

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 77 - Antwort auf die Briefe vom 18. Juni und 15. Juli 1800

u.a.: Deutschlandreise; Empfehlung eines Theaterstücks von Molière;

Na 1 Nachlass Max Horkheimer, 15 - Korrespondenzen u.a. mit Hans Fried (p. I 8, 1-201)

11 Briefe zwischen Hans Fried und Max Horkheimer, 1938-1940; 1 Brief von Max Horkheimer an die Albert Teachers Agency New York, 21.03.1941; 2 Briefe zwischen dem American Committee for International Studies, Princeton, New York und Max Horkheimer, 11.01.1941, 16.01.1941; 1 Brief von Sullivan & Cromwell New York an Max Horkheimer, 18.03.1940; 12 Briefe zwischen der Columbia University in the City of New York und Max Horkheimer, 1938-1940; 2 Briefe von Hans Fried an die Columbia University in the City of New york, 1938-1939; 1 Brief von Max Horkheimer an das Emergency Committee in Aid of Displaced German Scholars New York; 2 Briefe zwischen der Ittleson Foundation New York und Max Horkheimer, 19.11.1938, 28.11.1938; 1 Brief von Max Goldschmidt an Hans Fried, 21.04.1938; 1 Brief von Max Horkheimer an Max Goldschmidt, 25.04.1938; 2 Briefe von Alice Friedlaender an Max Horkheimer, 1932, 1944; 3 Briefe zwischen Charles S. Friedman und Max Horkheimer, 21.03.1942, 1936, 1942; 4 Briefe von C. J. Friedrich an Max Horkheimer, 1941; 4 Briefe von Franz L. Neumann an C. J. Friedrich, 1941; 8 Briefe zwischen den Friends of Europe London und Max Horkheimer, 1934-1938; 3 Briefe von Max Horkheimer an John W. Fries, 1939; 2 Briefe von Gertrud Fries an Max Horkheimer, 1936; 1 Brief von Josef Fröbes an Max Horkheimer, 24.08.1937; 3 Briefe zwischen Fruin und Max Horkheimer, 1936; 14 Briefe zwischen Eduard Fuchs und Max Horkheimer, 1935-1939;

Na 1 Nachlass Max Horkheimer, 14 - Korrespondenzen u.a. mit Hugo Fischer und Karl August Wittfogel (p. I 7, 224-429)

1 Brief von Max Horkheimer an Rosel Favez, 03.12.1935; 5 Briefe zwischen Sidney B. Fay von der Bureau of International Search Cambridge, Massachusetts und Max Horkheimer, 1939-1941; 1 Brief von Max Horkheimer an James Feibleman, 02.03.1942; 5 Briefe von Hans Feibelmann an Max Horkheimer, 1936-1937; 2 Briefe zwischen Babette Feigenbaum und Max Horkheimer, 29.04.1941, 05.05.1941; 1 Brief von Arthur Feiler an Max Horkheimer, 15.10.1939; 1 Brief von Max Horkheimer an Adolf Feitler, 03.01.1935; 3 Briefe zwischen Frederick V. Filed von dem American Council Institute of Pacific Relations und Max Horkheimer, 1937, 05.04.1937; 9 Briefe zwischen Thea Field, Lowell Field und Max Horkheimer, 1935-1941; 1 Brief von Max Horkheimer an Finkelstein, 18.09.1941; 7 Briefe zwischen Harry Finkelstein und Max Horkheimer, 1936-1940; 1 Brief von Louis Finkelstein an Robert MacIver, 29.05.1940; 2 Briefe zwischen Louis Finkelstein und Max Horkheimer, 06.06.1940, 04.06.1940; 15 Briefe zwischen Hugo Fischer und Max Horkheimer, 1937-1938; 1 Brief von Hugo Fischer an P. Tillich; 1 Brief von Hugo Fischer an Karl A. Wittfogel, 17.06.1940; 2 Briefe von Max Horkheimer an Ernest Manheim, April 1942; 1 Brief von Alexander Farquharson an Max Horkheimer, 20.01.1940; 3 Briefe zwischen dem Institute of International Education, New York Edgar J. Fisher und Max Horkheimer, Oktober 1938, 18.10.1938; 10 Briefe zwischen Paul Fischer und Max Horkheimer, 1938-1940; 2 Briefe zwischen der Hessian Hills School New York und Max Horkheimer, 21.02.1938, 28.02.1938; 2 Briefe zwischen Dorothy Canfield Fisher und Max Horkheimer, 24.01.1939, 19.01.1939; 1 Brief von Ossip K. Flechtheim an Max Horkheimer, 04.01.1941; 2 Briefe zwischen der University of Minnesota, Minneapolis und Max Horkheimer, 02.08.1945, 15.09.1945; 3 Briefe zwischen Leo Löwenthal und Max Horkheimer, 1943-1945, 17.08.1945; 2 Briefe zwischen der University of Denver, Colorado und Max Horkheimer, 11.05.1943, 28.05.1943; 1 Brief von dem Institute Universitaire De Hautes Etudes Internationales Genf an Max Horkheimer, 25.01.1939; 1 Brief von Hans Kelsen an Max Horkheimer, 30.01.1939; Lebenslauf und 2 Empfehlungsschreiben von Max Fleischmann für Prof. Edwin Borchard; 1 Brief von der Columbia University in the City of New York an Franz Neumann, 17.04.1940; 3 Briefe zwischen Philipp Flesch und Max Horkheimer, 26.03.1940, 1939-1940; 17 Briefe zwischen Babette Fletcher, Theo Fletcher und Max Horkheimer, 1941-1950; 1 Brief von Max Horkheimer an Abraham Flexner, 07.06.1939; 1 Brief von Robert Fließ an Max Horkheimer, 24.10.1938; 1 Brief von der Foreign Policy Association New York an Max Horkheimer, 03.11.1934; 1 Brief von Max Horkheimer an Rudolf Forster, 10.01.1940; 2 Briefe von der Fortune Time & Life Building New York und Max Horkheimer, 1938-1940; 4 Briefe zwischen Siegmund H. Foulkes (Fuchs) und Max Horkheimer, 1936-1937, 31.12.1936; 5 Briefe zwischen Elsie M. Foulstone und Max Horkheimer, 1941; 1 Brief von Mary Fox an Max Horkheimer, 09.12.1938; 5 Briefe zwischen Ernst Fraenkel und Max Horkheimer, 1936-1938; 1 Heiratsanzeige Liesl Frank; 7 Briefe zwischen Philipp Frank und Max Horkheimer, 1937-1939; 6 Briefe zwischen Lothar G. Frank und Max Horkheimer, 1941; 7 Briefe zwischen Felix Frankfurter und Max Horkheimer, 1937-1941; 2 Briefe zwischen Joseph Freeman und Max Horkheimer, 22.11.1944; 1 Brief von der Free Synagogue New York an Max Horkheimer, 14.11.1938; 2 Briefe zwsichen Benjamin Freilichmann und Max Horkheimer, 07.01.1939, 23.01.1939; 2 Briefe zwischen dem Frenkel Travel Service New York und Max Horkheimer, 21.02.1936, 23.02.1936; 2 Briefe zwischen Hugo Freund und Max Horkheimer, 14.11.1938, 18.11.1938; 2 Briefe zwischen Julius A. Jr. Freynick und Max Horkheimer, 11.09.1939, 18.09.1939;